CN102026634B - 诱导肿瘤缺氧以治疗癌症 - Google Patents

诱导肿瘤缺氧以治疗癌症 Download PDF

Info

Publication number
CN102026634B
CN102026634B CN200980102782.7A CN200980102782A CN102026634B CN 102026634 B CN102026634 B CN 102026634B CN 200980102782 A CN200980102782 A CN 200980102782A CN 102026634 B CN102026634 B CN 102026634B
Authority
CN
China
Prior art keywords
tumor
stilbene
hypoxia
tirapazamine
amido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200980102782.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN102026634A (zh
Inventor
R·李
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Virginia Commonwealth University
Original Assignee
PLin
Virginia Commonwealth University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PLin, Virginia Commonwealth University filed Critical PLin
Priority to CN201310699012.3A priority Critical patent/CN104043125B/zh
Publication of CN102026634A publication Critical patent/CN102026634A/zh
Application granted granted Critical
Publication of CN102026634B publication Critical patent/CN102026634B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN200980102782.7A 2008-04-10 2009-04-08 诱导肿瘤缺氧以治疗癌症 Active CN102026634B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310699012.3A CN104043125B (zh) 2008-04-10 2009-04-08 诱导肿瘤缺氧以治疗癌症

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4396408P 2008-04-10 2008-04-10
US61/043,964 2008-04-10
PCT/US2009/039899 WO2009126705A2 (en) 2008-04-10 2009-04-08 Induction of tumor hypoxia for cancer therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201310699012.3A Division CN104043125B (zh) 2008-04-10 2009-04-08 诱导肿瘤缺氧以治疗癌症

Publications (2)

Publication Number Publication Date
CN102026634A CN102026634A (zh) 2011-04-20
CN102026634B true CN102026634B (zh) 2014-01-22

Family

ID=41162569

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200980102782.7A Active CN102026634B (zh) 2008-04-10 2009-04-08 诱导肿瘤缺氧以治疗癌症
CN201310699012.3A Active CN104043125B (zh) 2008-04-10 2009-04-08 诱导肿瘤缺氧以治疗癌症

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201310699012.3A Active CN104043125B (zh) 2008-04-10 2009-04-08 诱导肿瘤缺氧以治疗癌症

Country Status (6)

Country Link
US (4) US8591921B2 (https=)
JP (2) JP5731372B2 (https=)
KR (1) KR101925436B1 (https=)
CN (2) CN102026634B (https=)
TW (1) TWI504391B (https=)
WO (1) WO2009126705A2 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2592103Y2 (ja) 1992-07-23 1999-03-17 東海旅客鉄道株式会社 ケーブルトラフ
CN102746336B (zh) 2005-06-29 2015-08-19 施瑞修德制药公司 氨基磷酸酯烷化剂前体药物
CN102026634B (zh) 2008-04-10 2014-01-22 弗吉尼亚州立邦联大学 诱导肿瘤缺氧以治疗癌症
WO2012009288A2 (en) * 2010-07-12 2012-01-19 Threshold Pharmaceuticals, Inc. Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer
EP2407161A1 (en) * 2010-07-13 2012-01-18 Sanofi An antitumoral combination comprising ombrabulin and bevacizumab
US9402820B2 (en) 2011-04-22 2016-08-02 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Use of pyruvate or succinate to enhance the efficacy of a hypoxia activated prodrug for the treatment of tumors
WO2013096687A1 (en) 2011-12-22 2013-06-27 Threshold Pharmaceuticals, Inc. Administration of hypoxia activated prodrugs in combination with chk1 inhibitors for treating cancer
CN102512692B (zh) * 2012-01-16 2014-07-16 北京大学 肿瘤靶向栓塞治疗组合物及其制备方法
AU2013204313C1 (en) * 2012-06-01 2016-04-07 Bionomics Limited Combination Therapy
US10071109B2 (en) 2013-11-06 2018-09-11 Molecular Templates, Inc. Predictive biomarker for hypoxia-activated prodrug therapy
CA2930001A1 (en) * 2013-11-11 2015-05-14 University Hospitals Cleveland Medical Center Targeted treatment of anerobic cancer
US9586056B2 (en) * 2014-07-03 2017-03-07 Haniva Llc Combination therapy for treating cancer and method for treating cancer using a combination therapy
CA2957552C (en) * 2014-08-08 2024-01-16 Vindico Nanobiotechnology, Llc Compositions and methods for inducing nanoparticle-mediated microvascular embolization of tumors
WO2016123313A1 (en) 2015-01-29 2016-08-04 Oxyrase, Inc. Methods for inhibiting tumor growth
EP3294313A4 (en) * 2015-05-15 2019-04-17 The General Hospital Corporation METHODS RELATING TO THE PREVENTION AND TREATMENT OF DRUG RESISTANCE
US10456452B2 (en) 2015-07-02 2019-10-29 Poseida Therapeutics, Inc. Compositions and methods for improved encapsulation of functional proteins in polymeric vesicles
KR20180086195A (ko) * 2015-10-21 2018-07-30 테크리슨 리미티드 면역 매개 암 치료를 위한 조성물 및 방법
ES2865481T3 (es) 2016-04-29 2021-10-15 Poseida Therapeutics Inc Micelas basadas en poli(histidina) para la complejación y el aporte de proteínas y ácidos nucleicos
CN108348463A (zh) * 2016-05-13 2018-07-31 泰克利森有限公司 用于治疗肝脏组织的方法
CN107007571B (zh) * 2017-02-24 2020-08-21 福州市传染病医院 肿瘤微酸性敏感的铜-药物共配位自组装纳米粒及应用
CN110051848A (zh) * 2019-05-06 2019-07-26 中国科学院长春应用化学研究所 药物组合、应用以及抗肿瘤的药物
CN110585214A (zh) * 2019-09-25 2019-12-20 湖北大学 一种促进治疗肿瘤效果的纳米粒子及其合成方法
CN110713596B (zh) * 2019-11-08 2022-04-29 西北师范大学 肿瘤无导管栓塞用pH-还原双响应高分子栓塞剂及其合成
CN112961082B (zh) * 2021-02-22 2022-09-06 沈阳药科大学 一种血管阻断剂与双载药仿生脂质体联用的给药系统
JP7730130B2 (ja) * 2021-03-02 2025-08-27 ドリームメディカルパートナーズ株式会社 塞栓材及びその製造方法
WO2023049207A1 (en) * 2021-09-22 2023-03-30 The University Of Texas System Quantitative magnetic resonance imaging and tumor forecasting
CN114344482B (zh) * 2022-01-14 2023-05-12 重庆医科大学附属第二医院 一种基于金属有机骨架的多功能纳米粒及其制备方法与应用
WO2024006901A1 (en) * 2022-06-29 2024-01-04 Diffusion Pharmaceuticals Llc Uses of bipolar trans carotenoids in the treatment of cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3980779A (en) 1972-02-01 1976-09-14 Bayer Aktiengesellschaft 3-Amino-1,2,4-benzotriazine-1,4-di-N-oxide compositions and method of using same
US5624925A (en) 1986-09-25 1997-04-29 Sri International 1,2,4-benzotriazine oxides as radiosensitizers and selective cytotoxic agents
US5175287A (en) 1986-09-25 1992-12-29 S R I International Process for preparing 1,2,4-benzotriazine oxides
ATE130517T1 (de) * 1990-08-08 1995-12-15 Takeda Chemical Industries Ltd Intravaskulär embolisierendes mittel mit gehalt an einem die angiogenesis hemmenden stoff.
EP1155689B1 (en) 1993-07-19 2006-09-20 Angiotech Pharmaceuticals, Inc. Anti-angiogenic stents and methods of their preparation
US5484612A (en) 1993-09-22 1996-01-16 The Board Of Trustees Of The Leland Stanford Junior University Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin
GB9404400D0 (en) 1994-03-07 1994-04-20 Wood Pauline J Potentiation of bioreductive agents
CA2281807C (en) 1997-03-07 2007-10-16 Sanofi Pharmaceuticals, Inc. Method of treating a tumor
DE10012120A1 (de) 2000-03-13 2001-09-27 Ktb Tumorforschungs Gmbh Therapeutische und diagnostische Ligandensysteme mit Transportmolekülbindenden Eigenschaften und diese enthaltende Arzneimittel
CN1555253A (zh) 2001-09-13 2004-12-15 ������ѧ�����о�Ժ 化疗栓塞用紫杉醇的油性组合物、制剂及它们的制造方法
WO2004064734A2 (en) * 2003-01-17 2004-08-05 Threshold Pharmaceuticals, Inc. Combination therapies for the treatment of cancer
US20060264388A1 (en) 2003-02-26 2006-11-23 Olga Valota Method for treating liver cancer by intrahepatic administration of nemorubicin
ITRM20030355A1 (it) 2003-07-18 2005-01-19 Sigma Tau Ind Farmaceuti Composti ad attivita' citotossica derivati della combretastatina.
US20080108664A1 (en) * 2005-12-23 2008-05-08 Liu Belle B Solid-state form of AMG 706 and pharmaceutical compositions thereof
CN102026634B (zh) 2008-04-10 2014-01-22 弗吉尼亚州立邦联大学 诱导肿瘤缺氧以治疗癌症

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
cis-3, 4", 5-Trimethoxy-3"-aminostilbene disrupts tumor vascular perfusion without damaging normal organ perfusion;David Durrant 等;《Cancer Chemother Pharmacology》;20080326;第63卷;第191-200页 *
Urban Emmenegger等.Low-Dose Metronomic Daily Cyclophosphamide and Weekly Tirapazamine: A Well-Tolerated Combination Regimen with Enhanced Efficacy That Exploits Tumor Hypoxia.《Cancer Research》.2006,第66卷(第3期),第1664-1674页. *

Also Published As

Publication number Publication date
US20140065139A1 (en) 2014-03-06
JP5944018B2 (ja) 2016-07-05
US20120087913A1 (en) 2012-04-12
JP2011516565A (ja) 2011-05-26
US9649316B2 (en) 2017-05-16
WO2009126705A8 (en) 2011-04-14
CN104043125A (zh) 2014-09-17
US10426779B2 (en) 2019-10-01
CN102026634A (zh) 2011-04-20
KR20110050583A (ko) 2011-05-16
KR101925436B1 (ko) 2018-12-05
JP5731372B2 (ja) 2015-06-10
US10159676B2 (en) 2018-12-25
JP2015110602A (ja) 2015-06-18
WO2009126705A3 (en) 2010-02-18
TWI504391B (zh) 2015-10-21
US20180050039A1 (en) 2018-02-22
TW201002312A (en) 2010-01-16
US20170224693A1 (en) 2017-08-10
US8591921B2 (en) 2013-11-26
CN104043125B (zh) 2018-01-12
HK1202057A1 (en) 2015-09-18
WO2009126705A2 (en) 2009-10-15

Similar Documents

Publication Publication Date Title
CN102026634B (zh) 诱导肿瘤缺氧以治疗癌症
Ishida et al. MRI-guided focused ultrasound enhances drug delivery in experimental diffuse intrinsic pontine glioma
Dings et al. Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells
Teicher et al. Antiangiogenic and antitumor effects of a protein kinase Cβ inhibitor in human T98G glioblastoma multiforme xenografts
CN101646442B (zh) 血管痉挛的治疗剂或预防剂
CN105338977A (zh) 艾日布林和乐伐替尼作为治疗癌症的联合疗法的用途
US11129830B2 (en) PAC-1 combination therapy
Jae et al. The antitumor effect and hepatotoxicity of a hexokinase II inhibitor 3-bromopyruvate: in vivo investigation of intraarterial administration in a rabbit VX2 hepatoma model
Cohen et al. Subcutaneous delivery of nanoconjugated doxorubicin and cisplatin for locally advanced breast cancer demonstrates improved efficacy and decreased toxicity at lower doses than standard systemic combination therapy in vivo
EP2296706B1 (en) Photochemical internalisation of tyrosine kinase inhibitors
JP2010502638A (ja) エンドセリンアゴニストの投与による放射線療法への腫瘍細胞の感作
WO2026061436A1 (zh) 泮托拉唑在制备msln-car-t细胞治疗脑转移瘤的增强剂中的应用
US20100035952A1 (en) Radiosensitizer Formulations and Methods for Use
HK1202057B (en) Induction of tumor hypoxia for cancer therapy
ten Hagen et al. Tumor vascular therapy with TNF: critical review on animal models
Skitzki et al. A phase 1 study of Intra-Arterial CBL0137 in extremity melanomas and sarcomas
Liu et al. A rat toxicological study of intra-arterial injection of Tirapazamine, a hypoxia-activating Cancer therapeutic agent, followed by hepatic artery ligation
US20050095196A1 (en) Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor
JP2004521929A (ja) イソクマリン誘導体を使用する腫瘍の放射線増感および／または化学相乗作用
Kosaka et al. 546: Angiotensin II Type 1 Receptor Antagonist as an Angiogenic Inhibitor in Prostate Cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Free format text: FORMER OWNER: LEE PECK-SUN

Effective date: 20130902

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20130902

Address after: Virginia

Applicant after: Univ Virginia Commonwealth

Address before: Virginia

Applicant before: Univ Virginia Commonwealth

Applicant before: P .lin

C14 Grant of patent or utility model
GR01 Patent grant
C53 Correction of patent of invention or patent application
CB03 Change of inventor or designer information

Inventor after: R *li

Inventor after: P *lin

Inventor before: R .li

Inventor after: Li Ruimin

Inventor after: Lin Baisun

Inventor before: R *li

Inventor before: P *lin

COR Change of bibliographic data

Free format text: CORRECT: INVENTOR; FROM: LEE RONALD LEE PECK-SUN TO: LI RUIMIN LIN BAISUN

Free format text: CORRECT: INVENTOR; FROM: LEE RONALD TO: LEE RONALD LEE PECK-SUN